Hertzman Johansson C, Egyhazi BS. BRAF inhibitors in cancer therapy. Pharmacol Ther. 2014;142(2):176–82. https://doi.org/10.1016/j.pharmthera.2013.11.011.

Article  CAS  PubMed  Google Scholar 

Braicu C, Buse M, Busuioc C, et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers (Basel). 2019;11(10):1618. https://doi.org/10.3390/cancers11101618.

Article  CAS  PubMed  Google Scholar 

Zhang W. BRAF inhibitors: the current and the future. Curr Opin Pharmacol. 2015;23:68–73. https://doi.org/10.1016/j.coph.2015.05.015.

Article  CAS  PubMed  Google Scholar 

Crispo F, Notarangelo T, Pietrafesa M, et al. BRAF inhibitors in thyroid cancer: clinical impact, mechanisms of resistance and future perspectives. Cancers (Basel). 2019;11(9):1388. https://doi.org/10.3390/cancers11091388.

Article  CAS  PubMed  Google Scholar 

Molina-Cerrillo J, San Roman M, Pozas J, et al. BRAF mutated colorectal cancer: new treatment approaches. Cancers (Basel). 2020;12(6):1571. https://doi.org/10.3390/cancers12061571.

Article  CAS  PubMed  Google Scholar 

Liu H, Nazmun N, Hassan S, et al. BRAF mutation and its inhibitors in sarcoma treatment. Cancer Med. 2020;9(14):4881–96. https://doi.org/10.1002/cam4.3103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salama AK, Flaherty KT. BRAF in melanoma: current strategies and future directions. Clin Cancer Res. 2013;19(16):4326–34. https://doi.org/10.1158/1078-0432.CCR-13-0779.

Article  CAS  PubMed  Google Scholar 

Halle BR, Johnson DB. Defining and targeting BRAF mutations in solid tumors. Curr Treat Options Oncol. 2021;22(4):30. https://doi.org/10.1007/s11864-021-00827-2.

Article  PubMed  Google Scholar 

McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–32. https://doi.org/10.1016/S1470-2045(14)70012-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65. https://doi.org/10.1016/S0140-6736(12)60868-X.

Article  CAS  PubMed  Google Scholar 

Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–15. https://doi.org/10.1016/S1470-2045(18)30142-6.

Article  CAS  PubMed  Google Scholar 

Balani AR, Grendell JH. Drug-induced pancreatitis : incidence, management and prevention. Drug Saf. 2008;31(10):823–37. https://doi.org/10.2165/00002018-200831100-00002.

Article  CAS  PubMed  Google Scholar 

Muluneh B, Buie LW, Collichio F. Vemurafenib-associated pancreatitis: case report. Pharmacotherapy. 2013;33(4):e43-44. https://doi.org/10.1002/phar.1208.

Article  PubMed  Google Scholar 

Ruan GJ, Goyal G, Shah MV, et al. Acute pancreatitis from treatment with BRAF inhibitors in Erdheim-Chester disease: a report from 2 tertiary referral centers. Pancreas. 2021;50(1):e6-8. https://doi.org/10.1097/MPA.0000000000001704.

Article  PubMed  Google Scholar 

Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16(4):359–65. https://doi.org/10.1002/pds.1323.

Article  PubMed  Google Scholar 

Khaleel MA, Khan AH, Ghadzi SMS, et al. A standardized dataset of a spontaneous adverse event reporting system. Healthcare (Basel). 2022;10(3):420. https://doi.org/10.3390/healthcare10030420.

Article  PubMed  Google Scholar 

Shu Y, Ding Y, Liu Y, et al. Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol. 2022;13: 862508. https://doi.org/10.3389/fphar.2022.862508.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao ZX, Yang TY, Wang YH, et al. Cardiovascular events of Bruton’s tyrosine kinase inhibitors: a real-world study based on the United States food and drug administration adverse event reporting system database. Br J Clin Pharmacol. 2024;90(9):2166–79. https://doi.org/10.1111/bcp.16127.

Article  CAS  PubMed  Google Scholar 

Ohyama K, Iida M, Akiyama S, et al. Time-to-onset analysis of rhabdomyolysis due to different proton pump inhibitors using a pharmacovigilance database. In Vivo. 2024;38(3):1285–91. https://doi.org/10.21873/invivo.13567.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li D, Wang H, Qin C, et al. Drug-induced acute pancreatitis: a real-world pharmacovigilance study using the FDA adverse event reporting system database. Clin Pharmacol Ther. 2024;115(3):535–44. https://doi.org/10.1002/cpt.3139.

Article  PubMed  Google Scholar 

Eland IA, Sundstrom A, Velo GP, et al. Antihypertensive medication and the risk of acute pancreatitis: the European case-control study on drug-induced acute pancreatitis (EDIP). Scand J Gastroenterol. 2006;41(12):1484–90. https://doi.org/10.1080/00365520600761676.

Article  CAS  PubMed  Google Scholar 

Chen CB, Chang HH, Chou SW, et al. Acute pancreatitis in children with acute lymphoblastic leukemia correlates with L-asparaginase dose intensity. Pediatr Res. 2022;92(2):459–65. https://doi.org/10.1038/s41390-021-01796-w.

Article  CAS  PubMed  Google Scholar 

Kureyama Y, Hanaoka Y, Tomita D, et al. Pancreatitis after treatment with encorafenib, binimetinib, and cetuximab for BRAF V600E mutation-positive colorectal cancer. Cureus. 2024;16(5): e60188. https://doi.org/10.7759/cureus.60188.

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Mao W, Liu D, et al. Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS). Front Pharmacol. 2023;14:1231320. https://doi.org/10.3389/fphar.2023.1231320.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alenzi KA, Alsuhaibani D, Batarfi B, et al. Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2024;15:1364110. https://doi.org/10.3389/fphar.2024.1364110.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang L, Mao W, Li X, et al. Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on food and drug administration adverse event report system database. Front Pharmacol. 2022;13: 977582. https://doi.org/10.3389/fphar.2022.977582.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang H, An Z, Zhao Y, et al. Tacrolimus related acute pancreatitis: an observational, retrospective. Pharmacovigil Study Clin Ther. 2024;46(7):524–8. https://doi.org/10.1016/j.clinthera.2024.04.005.

Article  CAS  Google Scholar